Aaron Kesselheim

Research Associate

Department of Health Policy and Management

Department of Health Policy and Management

Office address:
1620 Tremont St Suite 3030
Boston, MA 02120

Research interests

Dr. Kesselheim’s research focuses on the effects of intellectual property laws and federal and state policies on prescription drug and medical device development, the regulatory approval process, and the costs, availability, and use of therapeutics both domestically and in resource-poor settings. He has also investigated how other issues at the intersection of law and public health can affect health care delivery, including health care fraud, expert testimony in malpractice cases, and insurance reimbursement practices.

Selected publications

Kesselheim AS, Fischer MA, Avorn J.  Extensions of intellectual property rights and delayed adoption of generic drugs: effects on Medicaid spending. Health Affairs 2006;25:1637-1647.

Kesselheim AS and Mello MM.  Confidentiality laws and secrecy in medical research: improving access to drug safety data.  Health Affairs 2007;26:483-491.

Kesselheim AS and Avorn J. Pharmaceutical promotion to physicians and First Amendment rights.  New England Journal of Medicine 2008;358:1727-1732.

Kesselheim AS and Studdert DM. Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996-2005.  Annals Int Med 2008;149:342-349.

Kesselheim AS. Using market exclusivity incentives to promote pharmaceutical innovation. New England Journal of Medicine 2010;363:1855-1862.

Kesselheim AS.  Off-label drug use and promotion: balancing public health goals and commercial speech.  American Journal of Law and Medicine 2011;37:225-257.

Kesselheim AS, Murtagh L, Mello MM.  “Pay-for-delay” settlements of disputes over pharmaceutical patents.  New England Journal of Medicine 2011;365(15):1439-1445.

Kesselheim AS, Robertson CT, Myers JA, Rose SL, Gillet V, Ross KM, Glynn RJ, Joffe S, Avorn J. A randomized study of how physicians interpret research funding disclosures. New England Journal of Medicine 2012;367:1119-1127.

Kesselheim AS and Avorn J. The Food and Drug Administration has the legal basis to restrict promotion of flawed comparative effectiveness research. Health Affairs 2012;31:2200-2205.

Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, Choudhry NK. Variations in pill appearance of antiepileptic drugs and the risk of non-adherence. JAMA Internal Medicine 2012 Dec 31:1-7. doi: 10.1001/2013.jamainternmed.997.

Kesselheim AS, Mello MM, Avorn J.  FDA regulation of off-label drug promotion under attack. JAMA 2013;309(5):445-446.


M.P.H., 2007, Harvard School of Public Health

J.D. magna cum laude, 2002, University of Pennsylvania Law School

M.D., 2002, University of Pennsylvania School of Medicine

A.B. summa cum laude, 1996, History and Science, Harvard University